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‘Atypical Ugi’ tetrazoles†
Eman M. M. Abdelraheem,ab Imogen Goodwin,a Shabnam Shaabani, a
Michel P. de Haan,a Katarzyna Kurpiewska,c Justyna Kalinowska-Tłuścik c and
Alexander Dömling *a
Amino acid-derived isocyano amides together with TMSN3, oxo-
components and 18 or 28 amines are common substrates in the Ugi
tetrazole reaction. We surprisingly found that combining these
substrates gives two different constitutional isomeric Ugi products
A and B. A is the expected classical Ugi product whereas B is an
isomeric product (‘atypical Ugi’) of the same molecular weight with
the tetrazole heterocycle migrated to a different position. We
synthesized, separated and characterized 22 different isomorphic
examples of the two constitutional isomers of the Ugi reaction to
unambiguously prove the formation of A and B. Mechanistic studies
resulted in a proposed mechanism for the concomitant formation
of A and B.
1,5-Disubstituted tetrazoles are well-known bioisosteres of
carboxylic acids and cis-amides and thus widely used in
chemical biology and medicinal chemistry.1 One of the most
competitive synthetic pathways towards this important scaffold
is the Ugi tetrazole reaction (Scheme 1).2 Recently, we intro-
duced a straightforward way for the synthesis of a-, b- and
higher amino acid-derived isocyano amides.3 Isocyano acetamides
are very versatile building blocks and have been used in Ugi and
Passerini multicomponent reactions as well as in heterocycle
syntheses, for example for the synthesis of tetrazoles,4
imidazoles,5 iminohydantoins,6 oxazoles7 and for the produc-
tion of functional materials such as giant vesicles,8 PEGylated
polymers,9 proline-like b-turn mimics,10 functional b-sheet
mimics,11 tryptase and FXa inhibitors,12 inhibitors of hepatitis
C virus NS3 protease,13 Src-family kinase p56Lck inhibitors,14
erythropoietin mimicking small molecules,15 selenopeptido
mimetics,16 hydrogels,17 polyisocyanides for bioscaffolding,18
peptide ligations,19 polyamines,20 spirocycles,21 functionalized
fullerenes,22 natural product sandramycin,23 dendrimers24 and
artificial macrocycles25 (Fig. 1). The chemistry of isocyanoacetate
and derivatives has been recently comprehensively reviewed.26 In
an ongoing effort to synthesize diversely substituted macrocycles
using isocyanide based multicomponent reactions (IMCR), we
reported the first time use of the Ugi tetrazole variation for
macrocyclic ring closure using amino acid derived isocyanides.27
During analysis of several X-ray structures of tetrazole products
including macrocycles, we noted beside the formation of the
expected classical tetrazole products, the formation of constitu-
tional isomeric Ugi products in considerable amounts where
the tetrazole heterocycle was formally migrated from the iso-
cyanide position to the amide position introduced by the
amino acid-derived isocyano amide (Fig. 2). Surprised by the
unexpected formation of the atypical isomer we investigated
the reaction more thoroughly and want to report here synthesis
Scheme 1 Structures and yields of isocyano amides synthesized and used
in this study.
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and separation of 22 compounds, analytical and structural
evidence for the formation of both isomers, and a mechanistic
proposal.
We thoroughly investigated the structural influence of the
substrates and reaction conditions on the ratio of A/B. Numerous
examples were characterized by different means, 1H-NMR,
13C-NMR, 2D COSY and HMBC, for example in Fig. 3 the key
proton which is labeled by star * correlates to 157.5 ppm
(tetrazole-C) in compound 6i and correlates to 173.7 ppm
(carbonyl-C) in compound 7i (ESI†). Also, multiple compounds
were characterized by unambiguous X-ray structure analyses.
The dependency of the formation of A and B on the a-amino
acid isocyanide was investigated with glycine, phenylalanine,
tryptophan and valine. Thus, we synthesized several different
amino acid-derived isocyanides as their amides, by simply
mixing the amine and isocyanoester under solvent-free condi-
tions and generally could obtain the isocyanoamides in good to
excellent yields (Scheme 1). However, no influence of the amino
acid side chain towards A/B selectivity was observed. Isocyano-
amides are a-acidic and the pKa of an amide is 2–4 units lower
than the corresponding ester.26 Moreover, anionic a-isocyanides
are important intermediates in several heterocycle formations
such as oxazoles or oxazolidines.28 To investigate the potential
involvement of such isocyano carbaniones we reacted blocked
a,a-dimethyl isocyanoacetamide 3f. However, even with this
isocyanide, unable to form carbanions, the formation of A and
B was observed. Thus, an isocyano carbanion-based mechanism
could be ruled out.
More elucidating was the investigation of the dependency on
the distance between the isocyanide and the amide group, e.g.
derived from a-, b-, g-amino acids. As shown above, all a-amino
acid derived isocyanoacetamides 3a–3f gave mixtures of A and B
(Scheme 2). Also, b-amino acid b-alanine-derived isocyanide 3g
and 3h gave A and B, although only small amounts of B were
formed (Scheme 3). Even more pronounced with g-amino
acid derived 3i and 3j and with d-amino acid derived 3k no B
could be detected anymore by SFC analysis of the crude
reaction. Thus, a clear dependence of the A/B ratio on the
distance between the amide group and the isocyanide was
established.
Next, we investigated the formation of A and B in depen-
dency of the azide source. In the original description of the
tetrazole multicomponent reaction, Ugi used stock solutions of
hydrogen azide in benzene or alternatively amine hydrochloride
together with sodium azide. Later, TMS-azide was introduced as
a safe in situ hydrogen azide which now completely superseded
the isolation of the toxic and explosive hydrogen azide.
Fig. 1 Bioisostery of 1,5-disubstituted tetrazoles (A), tetrazole Ugi reac-
tion (B), isocyanoacetamide synthesis (C). Herein reported: surprising
finding of two constitutional Ugi tetrazole isomers (D).
Fig. 2 Observation of the ‘atypical Ugi’ tetrazole products besides
expected products, highlighted as red and green bolded structures respec-
tively and X-ray structures. In 6a the red dotted line indicates an intra-
molecular hydrogen bond (Trt = trityl).
Fig. 3 1H–1H COSY and 1H–13C HMBC correlations to differentiate
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Unfortunately, no difference in A to B ratio was observed using
different azide sources.
The formation of A and B dependent on the reaction
temperature was investigated by SFC-MS as shown in Fig. S1
in the ESI.† The change of the temperature of the reaction from
room temperature to 0 1C and 10 1C showed a slight increase
in the formation of the minor product B. Thus we speculate
that the minor product is the thermodynamic product, however
it did not greatly change the overall distribution of the major/
minor product. Several X-ray structures of the two products
A and B involving different substituents provide unambiguous
proof of the formation and give some first insight into possible
solid-state conformations (Fig. 2 and Fig. 4). The plausible
mechanism of the reaction is shown in Scheme 4. It is con-
ceivable that initially the condensation of the oxo-component
and amino group affords the Schiff base. Then, nucleophilic
addition of carbenoid C atom of the isocyanide onto the
iminium group followed by the addition of the azide anion
onto the C atom of the nitrilium ion and 1,5-dipolar electro-
cyclization leads to the formation of regioisomer A. On the
other hand, the nucleophilic addition of carbenoid C atom of
the isocyanide onto the iminium group with the addition of the
O atom of amide group onto the C atom of the nitrilium ion
formed oxazolidine intermediate which followed by the addition
of the azide anion leads to the formation of regioisomer B.
Similar oxazolidine intermediates were also previously
postulated in a macrocyclization and peptide formation.29
In conclusion, we report for the first time a competing Ugi
tetrazole reaction with commonly used isocyanoamides as
substrates. We investigated in detail the reaction by performing
many different substrate combinations, reaction conditions,
reagent conditions and standard chemical analyses and multiple
crystal structures. Based on our results and literature analysis we
propose a competing mechanism which is based on an intra-
molecular carbonyl oxygen attack to the isocyanide and addition
to the imine via a five- or six-membered intermediate. This
a-adduct intermediate preferentially reacts with the azide ion
to ultimately cyclize to the ‘atypical Ugi’ product. The knowledge
of this side reaction in the context of the Ugi tetrazole reaction is
of high importance since it is an often-used reaction in the
chemical community.
Scheme 2 ‘Crazy Ugi’ tetrazole products beside expected products from
a-amino acid derived isocyanoacetamides, highlighted as red and green
bolded structures respectively.
Scheme 3 Tetrazole products from b- and g-amino acid derived iso-
cyanoacetamides, highlighted as red and green bolded structures respec-
tively (Trt = trityl).
Fig. 4 X-ray structures for some ‘normal’ Ugi tetrazole products.
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S. Nerdinger, WO2001014320A1, 2001; (b) M. W. Cappi, T. Fuchs,
R. Eckl and S. Schabbert, WO2002016312A2, 2002.
13 S. Venkatraman, F. Velazquez, W. Wu, M. Blackman, K. X. Chen,
S. Bogen, L. Nair, X. Tong, R. Chase, A. Hart, S. Agrawal, J. Pichardo,
A. Prongay, K.-C. Cheng, V. Girijavallabhan, J. Piwinski, N.-Y. Shih
and F. G. Njoroge, J. Med. Chem., 2009, 52, 336.
14 P. Chen, D. Norris, E. J. Iwanowicz, S. H. Spergel, J. Lin, H. H. Gu,
Z. Shen, J. Wityak, T.-A. Lin, S. Pang, H. F. De Fex, S. Pitt, D. R. Shen,
A. M. Doweyko, D. A. Bassolino, J. Y. Roberge, M. A. Poss, B.-C. Chen,
G. L. Schieven and J. C. Barrish, Bioorg. Med. Chem. Lett., 2002, 12, 1361.
15 A. Domling, B. Beck, W. Baumbach and G. Larbig, Bioorg. Med.
Chem. Lett., 2007, 17, 379.
16 H. P. Hemantha and V. V. Sureshbabu, J. Pept. Sci., 2010, 16, 644.
17 M. Jaspers, A. E. Rowan and P. H. J. Kouwer, Adv. Funct. Mater., 2015,
25, 6503.
18 S. Le Gac, E. Schwartz, M. Koepf, J. J. L. M. Cornelissen, A. E. Rowan
and R. J. M. Nolte, Chem. – Eur. J., 2010, 16, 6176.
19 Y. Yuan, J. Zhu, X. Li, X. Wu and S. J. Danishefsky, Tetrahedron Lett.,
2009, 50, 2329.
20 T. Pirali, G. Callipari, E. Ercolano, A. A. Genazzani, G. B. Giovenzana
and G. C. Tron, Org. Lett., 2008, 10, 4199.
21 J. George, S.-Y. Kim and K. Oh, Org. Lett., 2018, 20, 7192.
22 B. B. Ravanello, N. Seixas, O. E. D. Rodrigues, R. S. da Silva,
M. A. Villetti, A. Frolov, D. G. Rivera and B. Westermann, Chem. –
Eur. J., 2018, 24, 9788.
23 K. Katayama, K. Nakagawa, H. Takeda, A. Matsuda and S. Ichikawa,
Org. Lett., 2014, 16, 428.
24 X.-X. Deng, F.-S. Du and Z.-C. Li, ACS Macro Lett., 2014, 3, 667.
25 B. Beck, G. Larbig, B. Mejat, M. Magnin-Lachaux, A. Picard,
E. Herdtweck and A. Domling, Org. Lett., 2003, 5, 1047.
26 A. V. Gulevich, A. G. Zhdanko, R. V. A. Orru and V. G. Nenajdenko,
Chem. Rev., 2010, 110, 5235.
27 E. M. M. Abdelraheem, M. P. de Haan, P. Patil, K. Kurpiewska,
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